Anson K. Abraham

521 total citations
17 papers, 353 citations indexed

About

Anson K. Abraham is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Anson K. Abraham has authored 17 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Oncology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Anson K. Abraham's work include Monoclonal and Polyclonal Antibodies Research (7 papers), Protein purification and stability (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Anson K. Abraham is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), Protein purification and stability (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Anson K. Abraham collaborates with scholars based in United States, Israel and South Korea. Anson K. Abraham's co-authors include Donald E. Mager, John M. Harrold, Leonid Kagan, Wojciech Krzyżański, Anup Zutshi, Bianca Weinstock‐Guttman, Murali Ramanathan, Ravit Geva, Nehal J. Lakhani and Aman P. Singh and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, Annals of Oncology and Biochemical Pharmacology.

In The Last Decade

Anson K. Abraham

17 papers receiving 339 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anson K. Abraham United States 12 152 138 110 103 29 17 353
Zinnia P. Parra‐Guillén Spain 13 171 1.1× 112 0.8× 74 0.7× 61 0.6× 31 1.1× 38 388
Xueyan Wang China 5 81 0.5× 240 1.7× 94 0.9× 48 0.5× 53 1.8× 7 391
Anne Marie Bertucci United States 7 76 0.5× 82 0.6× 154 1.4× 29 0.3× 23 0.8× 7 332
Michelle DuPont United States 7 92 0.6× 133 1.0× 80 0.7× 38 0.4× 17 0.6× 13 288
Liviawati Sutjandra United States 7 102 0.7× 172 1.2× 64 0.6× 88 0.9× 41 1.4× 9 330
Bei Wang United States 10 66 0.4× 261 1.9× 47 0.4× 219 2.1× 24 0.8× 32 349
Biyu Zhang China 10 218 1.4× 80 0.6× 85 0.8× 32 0.3× 67 2.3× 23 342
Alfonsus Johannes Maria van den Eertwegh Netherlands 10 102 0.7× 181 1.3× 77 0.7× 20 0.2× 60 2.1× 24 290
Liubo Chen China 12 144 0.9× 136 1.0× 38 0.3× 38 0.4× 56 1.9× 21 395
Anja Baier Germany 5 232 1.5× 86 0.6× 101 0.9× 23 0.2× 56 1.9× 7 446

Countries citing papers authored by Anson K. Abraham

Since Specialization
Citations

This map shows the geographic impact of Anson K. Abraham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anson K. Abraham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anson K. Abraham more than expected).

Fields of papers citing papers by Anson K. Abraham

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anson K. Abraham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anson K. Abraham. The network helps show where Anson K. Abraham may publish in the future.

Co-authorship network of co-authors of Anson K. Abraham

This figure shows the co-authorship network connecting the top 25 collaborators of Anson K. Abraham. A scholar is included among the top collaborators of Anson K. Abraham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anson K. Abraham. Anson K. Abraham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Marathe, Dhananjay, Huub Jan Kleijn, Anne Chain, et al.. (2024). Exposure–Response Analyses for Belzutifan to Inform Dosing Considerations and Labeling. The Journal of Clinical Pharmacology. 64(10). 1246–1258. 2 indexed citations
2.
Marathe, Dhananjay, Huub Jan Kleijn, Anne Chain, et al.. (2023). Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling. CPT Pharmacometrics & Systems Pharmacology. 12(10). 1499–1510. 11 indexed citations
3.
Garralda, Elena, Ammar Sukari, Nehal J. Lakhani, et al.. (2022). A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. ESMO Open. 7(6). 100639–100639. 65 indexed citations
4.
Chatterjee, Manash, Mallika Lala, Anson K. Abraham, et al.. (2021). Pivotal Dose of Pembrolizumab: A Dose‐Finding Strategy for Immuno‐Oncology. Clinical Pharmacology & Therapeutics. 110(1). 200–209. 20 indexed citations
5.
6.
Tang, Huaping, et al.. (2019). Development and validation of a multiplexed drug level assay in support of combination biologics therapy clinical studies. Journal of Pharmaceutical and Biomedical Analysis. 171. 204–211. 5 indexed citations
7.
Tiwari, Abhinav, et al.. (2016). Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling. The AAPS Journal. 19(2). 510–519. 15 indexed citations
8.
Tiwari, Abhinav, et al.. (2016). Assessing the Impact of Tissue Target Concentration Data on Uncertainty in In Vivo Target Coverage Predictions. CPT Pharmacometrics & Systems Pharmacology. 5(10). 565–574. 7 indexed citations
9.
Zutshi, Anup, et al.. (2015). Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies. Journal of Pharmacokinetics and Pharmacodynamics. 42(1). 1–18. 22 indexed citations
10.
Singh, Aman P., Wojciech Krzyżański, Steven W. Martin, et al.. (2014). Quantitative Prediction of Human Pharmacokinetics for mAbs Exhibiting Target-Mediated Disposition. The AAPS Journal. 17(2). 389–399. 40 indexed citations
11.
Harrold, John M. & Anson K. Abraham. (2014). Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment. Journal of Pharmacokinetics and Pharmacodynamics. 41(2). 141–151. 12 indexed citations
12.
Abraham, Anson K., Tristan S. Maurer, Amit S. Kalgutkar, et al.. (2011). Pharmacodynamic Model of Parathyroid Hormone Modulation by a Negative Allosteric Modulator of the Calcium-Sensing Receptor. The AAPS Journal. 13(2). 265–273. 9 indexed citations
13.
Abraham, Anson K., et al.. (2010). Type I Interferon Receptor is a Primary Regulator of Target-Mediated Drug Disposition of Interferon-β in Mice. Journal of Pharmacology and Experimental Therapeutics. 334(1). 327–332. 16 indexed citations
14.
Kagan, Leonid, Anson K. Abraham, John M. Harrold, & Donald E. Mager. (2010). Interspecies Scaling of Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Type I Interferons. Pharmaceutical Research. 27(5). 920–932. 40 indexed citations
15.
Abraham, Anson K., Murali Ramanathan, Bianca Weinstock‐Guttman, & Donald E. Mager. (2009). Mechanisms of interferon-β effects on bone homeostasis. Biochemical Pharmacology. 77(12). 1757–1762. 35 indexed citations
16.
Abraham, Anson K., Donald E. Mager, Xiang Gao, et al.. (2009). Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Parathyroid Hormone-Calcium Homeostasis in Rats and Humans. Journal of Pharmacology and Experimental Therapeutics. 330(1). 169–178. 20 indexed citations
17.
Abraham, Anson K., Wojciech Krzyżański, & Donald E. Mager. (2007). Partial derivative—Based sensitivity analysis of models describing target-mediated drug disposition. The AAPS Journal. 9(2). E181–E189. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zinnia P. Parra‐Guillén Breakdown of academic impact, for papers by Xueyan Wang Breakdown of academic impact, for papers by Anne Marie Bertucci Breakdown of academic impact, for papers by Michelle DuPont Breakdown of academic impact, for papers by Liviawati Sutjandra Breakdown of academic impact, for papers by Bei Wang Breakdown of academic impact, for papers by Biyu Zhang Breakdown of academic impact, for papers by Alfonsus Johannes Maria van den Eertwegh Breakdown of academic impact, for papers by Liubo Chen Breakdown of academic impact, for papers by Anja Baier
Rankless by CCL
2026